24H Stock Chart & Stats
€3.18
-€0.06(-1.91%)
At close: 4:00 PM EDT
€3.18
-€0.06(-1.91%)
Day’s Range― - ―
52-Week Range€2.19 - €3.80
Previous CloseN/A
Volume0.00
Average Volume (3M)283.00
Market Cap
€319.21M
Enterprise Value€4.01K
Total Cash (Recent Filing)€552.81M
Total Debt (Recent Filing)€1.03B
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 05, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume590
30 Day Avg. Volume283
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.39Price Target Upside195.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€40.29M
Bulls Say, Bears Say
Bulls Say
Phase III Clinical Efficacy (ConfideS/PAES)Robust, confirmatory Phase III data materially de-risks the core clinical hypothesis behind imlifidase. Statistically significant kidney function and dialysis‑reduction outcomes strengthen regulatory submissions, payer discussions and clinician adoption, supporting durable commercial uptake if approvals convert.
SERB Out‑licensing Materially Strengthens LiquidityThe EUR 110m upfront provides a meaningful, structural improvement to cash reserves and runway, lowering immediate refinancing pressure. This financing supports US launch investments, regulatory activities and commercialization execution, reducing insolvency risk while longer‑term revenues ramp.
U.S. Launch Readiness And Sizable Addressable MarketDefined US launch plan, experienced hires and targeting of the top ~100 transplant centers position the company to scale commercially. Combined with a large ~$2bn addressable market and strong product margins, successful execution could sustainably expand revenue and leverage fixed commercial costs.
Bears Say
Persistent Cash Burn And Revenue DeclineA deep TTM revenue decline paired with prolonged negative operating and free cash flow indicates structural cash‑generation weakness. Even with one‑off financing, the company remains dependent on external capital until product sales sustainably outpace operating burn, raising dilution and execution risk.
Negative Equity And Elevated Total DebtNegative shareholders' equity combined with sizable debt increases refinancing and solvency risk and constrains strategic optionality. Heavy leverage limits flexibility for M&A or sustained commercial investment, raises cost of capital and magnifies the impact of further operating misses on long‑term viability.
Commercial Adoption And Reimbursement HurdlesEven with approval, uptake depends on complex hospital reimbursement mechanics, NTAP/DRG alignment and center operational readiness. These structural barriers can materially slow revenue scale, keep SG&A elevated for longer, and delay cash flow breakeven despite clinical efficacy.
24H FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was €2.19 and its highest was €3.80 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is €319.21M.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 92 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -€0.232 earnings per share for the quarter, missing the consensus estimate of -€0.03 by -€0.201.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 0.52.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -€0.232 in its last earnings report, missing expectations of -€0.03. Following the earnings report the stock price went up 2.383%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in DE:24H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
24H Stock 12 Month Forecast
Average Price Target
€9.39
▲(195.35% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―